|
 |
|||||||
 |
PRESS RELEASES ADVENTRX to Present at the BIO InvestorForum 2005 on October 19 SAN DIEGO – October 13, 2005 – ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) today announced that Evan M. Levine, president and CEO, will present at the BIO InvestorForum 2005 on Wednesday, October 19 at 2:00 p.m. Pacific Time, in San Francisco at the Palace Hotel. A link to the live audio webcast presentation will be available via the "Investors" section of the Company's Web site at www.adventrx.com/investors/events.htm. This presentation will be available on the ADVENTRX Web site for 14 days. Attendees will include institutional investors, venture and private equity investors, as well as research analysts and bankers representing leading banks in the sector. Additional conference details and online registration are available at www.bio.org. About ADVENTRX ADVENTRX Pharmaceuticals is a biopharmaceutical research and development company focused on introducing new technologies for anticancer and antiviral treatments that improve the performance and safety of existing drugs, by addressing significant problems such as drug metabolism, toxicity, bioavailability and resistance. The Company's lead compound, CoFactor™, is a biomodulator of 5-fluorouracil (5-FU), a widely used cancer chemotherapy. CoFactor is currently being tested with 5-FU in a US-based Phase II and an EU-based Phase IIb clinical trial as a first line treatment of metastatic colorectal cancer. In addition, CoFactor has received clearance under a special protocol assessment from the FDA to begin a Phase III pivotal clinical trial for metastatic colorectal cancer. More information can be found on the Company's Web site at www.adventrx.com. Forward Looking Statement This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the FDA and other regulatory agencies. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in the Company's last quarterly report on Form 10-Q, as well as other reports that the Company files from time to time with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof.
Contact:
ADVENTRX Pharmaceuticals Andrea Lynn 858-552-0866
Investor Contact:
Lippert Heilshorn & Associates Jody Cain (jcain@lhai.com) Brandi Floberg (bfloberg@lhai.com) 310-691-7100 |
